Drug results: 1

pacritinib Pacritinib is a kinase inhibitor with activity against Janus-associated kinase 2 (JAK2) and Fms-like receptor tyrosine kinase 3 (FLT3). Pacritinib inhibits both wild-type JAK2 and the JAK2V617F mutant form that is common in patients with myeloproliferative neoplasms. Pacritinib also exhibits inhibitory activity against additional cellular kinases (such as colony-stimulating factor 1 and interleukin 1 receptor-associated kinase 1), the clinical relevance of which is unknown.

Featured News

Drugcentral 2023 NAR Article

The Latest in Chemistry in Coronavirus Research


Drugs in the News


Makena Venetoclax Dapagliflozin KEYTRUDA Sacubitril LORBRENA Hydroxychloroquine


DrugCentral Search Overview